144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial - PubMed

5 hours ago

Bulevirtide monotherapy for chronic hepatitis D (CHD) was shown to be safe and effective over 144 weeks, with continued improvement in HDV RNA undetectability rates with longer treatment duration.
Response rates (virologic, combined, and ALT normalization) decreased after treatment discontinuation, but a subset of patients maintained sustained undetectable HDV RNA during 96 weeks of posttreatment follow-up.
The duration of continuous HDV RNA undetectability at the end of treatment was the strongest predictor of sustained virologic response after discontinuation, allowing some patients to stop treatment without relapse.

Hasty Briefsbeta